Abstract
MicroRNAs (miRNAs) have been shown to have an important role in various cellular processes, such as apoptosis, differentiation and development. Recent studies have shown that miRNAs are mis-expressed in human cancers where they can exert their effect as oncogenes or tumor suppressors. Here, we review the potential for using miRNAs as biomarkers for diagnosis, prognosis and cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bartel DP . (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.
Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP et al. (2007). MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901–1908.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L et al. (2008). The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271–1277.
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524–15529.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999–3004.
Chan JA, Krichevsky AM, Kosik KS . (2005). MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029–6033.
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40: 43–50.
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I et al. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68: 8535–8540.
Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD et al. (2009). A let-7 microRNA-binding site polymorphism in the KRAS 3′ UTR is associated with reduced survival in oral cancers. Carcinogenesis 30: 1003–1007.
Ciafre SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351–1358.
Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK . (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8: 1055–1066.
Ebert MS, Neilson JR, Sharp PA . (2007). MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4: 721–726.
Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452: 896–899.
Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87–98.
Esquela-Kerscher A, Slack FJ . (2006). Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6: 259–269.
Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L et al. (2008). The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759–764.
Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C et al. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 67: 2456–2468.
Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, Ponzoni M et al. (2009). Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63–66.
Gillies JK, Lorimer IA . (2007). Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6: 2005–2009.
He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. (2005a). The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075–19080.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. (2005b). A microRNA polycistron as a potential human oncogene. Nature 435: 828–833.
Hermeking H . (2009). The miR-34 family in cancer and apoptosis. Cell Death Differ; e-pub ahead of print 22 May 2009.
Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD . (2001). A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science 293: 834–838.
Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243–3248.
Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O et al. (2008). Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451: 1125–1129.
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D et al. (2007). The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713–7722.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635–647.
Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K et al. (2005). Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96: 111–115.
Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K et al. (2009). The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene 28: 2419–2424.
Ketting RF, Fischer SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH . (2001). Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev 15: 2654–2659.
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017.
Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685–689.
Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA et al. (2008). Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903–3908.
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T . (2007). Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673–677.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672–675.
Lee RC, Feinbaum RL, Ambros V . (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843–854.
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J et al. (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415–419.
Lee YS, Dutta A . (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21: 1025–1030.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. (2005). MicroRNA expression profiles classify human cancers. Nature 435: 834–838.
Mayr C, Hemann MT, Bartel DP . (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576–1579.
Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al. (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113–2129.
Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R et al. (2008). Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359: 2641–2650.
Michael MZ, O’Connor SM, van Holst Pellekaan NG, Young GP, James RJ . (2003). Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882–891.
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513–10518.
O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT . (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843.
Pandey AK, Agarwal P, Kaur K, Datta M . (2009). MicroRNAs in diabetes: tiny players in big disease. Cell Physiol Biochem 23: 221–232.
Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA . (2007). Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg 194: 833–837; discussion 837–838.
Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH . (2009). Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42–46.
Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE et al. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901–906.
Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M et al. (2008). MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462–469.
Roush S, Slack FJ . (2008). The let-7 family of microRNAs. Trends Cell Biol 18: 505–516.
Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P et al. (2007). MicroRNA Let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67: 9762–9770.
Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA et al. (2007). Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104: 11400–11405.
Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY . (2007). miR-21-mediated tumor growth. Oncogene 26: 2799–2803.
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al. (2004). Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753–3756.
Taylor DD, Gercel-Taylor C . (2008). MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13–21.
Vester B, Wengel J . (2004). LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 43: 13233–13241.
Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A et al. (2007). Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 26: 7590–7595.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257–2261.
Wang S, Olson EN . (2009). AngiomiRs—key regulators of angiogenesis. Curr Opin Genet Dev 19: 205–211.
Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M et al. (2007). MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 67: 11111–11116.
Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. (2007a). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.
Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S et al. (2008). MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48–57.
Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E et al. (2007b). Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35: 4535–4541.
Zorio E, Medina P, Rueda J, Millan JM, Arnau MA, Beneyto M et al. (2009). Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem 7: 82–90.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trang, P., Weidhaas, J. & Slack, F. MicroRNAs as potential cancer therapeutics. Oncogene 27 (Suppl 2), S52–S57 (2008). https://doi.org/10.1038/onc.2009.353
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.353
Keywords
This article is cited by
-
Diagnosis of Pancreatic Cancer Using miRNA30e Biosensor
Interdisciplinary Sciences: Computational Life Sciences (2022)
-
miRkit: R framework analyzing miRNA PCR array data
BMC Research Notes (2021)
-
A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Non-coding RNAs: the new central dogma of cancer biology
Science China Life Sciences (2021)
-
MicroRNA-143 targets MAPK3 to regulate the proliferation and bone metastasis of human breast cancer cells
AMB Express (2020)